Drug
GS 2426
GS 2426: highest development phase Phase 1, developed by Gilead Sciences. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Gilead Sciences
Trials
| Drug | Phase | Indication |
|---|---|---|
| GS-2426 NCT07601243 | Phase 1 | Advanced Solid Tumors |
Latest
No recent events.
Follow GS 2426 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.